Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
Christopher Buckley, Jesus A Simón-Campos, Vyacheslav Zhdan, Brandon Becker, Katherine Davy, Elena Fisheleva, Anubha Gupta, Carol Hawkes, David Inman, Mark Layton, Nina Mitchell, Jatin Patel, Didier Saurigny, Russell Williamson, Paul P. Tak
Research output: Contribution to journal › Article › peer-review
4Citations
(Scopus)
449Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study'. Together they form a unique fingerprint.